LinkedIn

Andrew Mancini is the Director of Corporate Development and Strategy at MaxCyte, specializing in cell and gene therapies. He collaborates with MaxCyte’s partners around the world to advance novel cell engineering workflows for cellular therapeutics through strategic partnerships, acquisitions, and scientific and commercial strategy development. Prior to his time at MaxCyte, Andrew completed his PhD in Biomedical Sciences at the University of California, San Francisco, and completed his postdoctoral training at Genentech in Molecular Oncology. He has a broad range of experience and expertise that encompasses non-viral and viral engineering of primary immune cells, stem cells and cell lines at both research and manufacturing scales.